October 13, 2016 – Curant Health COO, Marc O’Connor, in Managed Healthcare Executive – Adherence in real-world conditions, streamlining prior authorizations and securing stakeholder buy in on the price/value curve can reign in drug spending no matter who becomes president. Here are three ways to help reign in drug costs.

1.    Focus on adherence in real-world conditionsEarlier this year, Curant Health released early results of our C The Cure program for a cohort of hepatitis C patients co-infected with HIV. The study showed that 90% of patients co-infected with hepatitis C virus (HCV) and HIV who enrolled in Curant Health’s C The Cure program experienced sustained virological response at 12 weeks (SVR12) post treatment. This is the only second real-world data set known for HCV patients with this profile and treatment regimen. The patient cohort included HCV patients who were both treatment experienced and treatment naïve. Participants were predominantly infected with HCV genotype 1 and most had followed treatment regimens, such as Harvoni or Sovaldi.

“It’s one thing to achieve high cure rates in tightly controlled clinical trials, but achieving high cure rates in real-world conditions for co-infected patients who have difficulty accessing therapies is something else entirely,” says Vickie Andros, PharmD, director of clinical services for Curant Health. “The ability to overcome challenges related to access and helping patients maintain outstanding adherence to their medication regimens allow us to achieve positive outcomes like these.”

According to IMS Health Informatics, medication nonadherence remains the longest lever available to impact more than $200 billion in wasted healthcare spending.

To read Marc’s full article, visit Managed Healthcare Executive.

To learn more about Curant Health, contact Kristin Lindsey, Senior Marketing Director, at klindsey@curanthealth.com.